Hautklinik, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität
- Address
- lock Available on a paid plan
Hautklinik, Klinikum Nürnberg - Advanced Melanoma Research Center
The Hautklinik at Klinikum Nürnberg, affiliated with the Paracelsus Medical Private University, is a leading dermatology research center specializing in advanced melanoma therapeutics. The center demonstrates particular expertise in BRAF-mutated melanoma and cutting-edge combination immunotherapy approaches for patients with metastatic and unresectable locally advanced disease.
- Phase 3 clinical trials in BRAF V600E/K mutation-positive melanoma
- Targeted therapy combinations with MEK and BRAF inhibitors (encorafenib and binimetinib)
- Immunotherapy integration with checkpoint inhibitors (pembrolizumab)
The clinic's research portfolio focuses on innovative triplet therapy regimens that combine molecular targeted agents with immunotherapy, representing the forefront of precision oncology in dermatologic malignancies. Their participation in pivotal registration trials underscores their commitment to establishing new treatment standards for patients with advanced melanoma who harbor specific genetic mutations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hautklinik, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Double-Blind Trial of Encorafenib, Binimetinib, and Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresectable Melanoma | Pfizer Inc. | Phase III | Not Recruiting | Sep 2021 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Binimetinib | 1 | Unknown | 2021-09-16 | 2021-09-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.